^
    Back
    Association details:
    Biomarker:EZH2 mutation
    Cancer:Follicular Lymphoma
    Drug:Ezharmia (valemetostat) (EZH2 inhibitor, EZH1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA

    Excerpt:
    ...Patient being successfully tested for EZH2 mutation status at study specific laboratories (for cohort 1, 2 and 2bis)11. ...
    Trial ID:
    2020-005225-81
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

    Excerpt:
    ...Patient being successfully tested for EZH2 mutation status at study specific laboratories (for cohort 1, 2 and 2bis) 11....
    Trial ID:
    NCT04842877
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    1731 Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial

    Published date:
    11/02/2023
    Excerpt:
    A gain-of-function EZH2 mutation was identified in 1 pt with FL, and this pt achieved a partial response. Median time to response overall was 3.7 (range 1.9–10.1) months (mo) and estimated median DOR for the 9 responding pts was 18.4...Valemetostat demonstrated encouraging clinical activity in pts with R/R B-NHL...Clinical responses were durable, with a median DOR of > 1.5...